| 王晓玲,张晓艳,苑玉聪,王学敏,赵 讯.肾康注射液对伴高同型半胱氨酸血症高血压肾病患者肾功能和心功能的影响[J].,2018,(8):1560-1564 |
| 肾康注射液对伴高同型半胱氨酸血症高血压肾病患者肾功能和心功能的影响 |
| Effect of Shenkang Injection on the Renal and Cardiac Function of Hypertensive Nephropathy Patients complicated with Hyperhomocysteinemia |
| 投稿时间：2017-07-23 修订日期：2017-08-18 |
| DOI：10.13241/j.cnki.pmb.2018.08.034 |
| 中文关键词: 肾康注射液 高同型半胱氨酸血症 高血压肾病 肾功能 心功能 |
| 英文关键词: Shenkang injection Hyperhomocysteinemia Hypertensive nephropathy Renal function Cardiac function |
| 基金项目:河北省科技厅科技攻关项目(042761100） |
|
| 摘要点击次数: 436 |
| 全文下载次数: 336 |
| 中文摘要: |
| 摘要 目的：探讨肾康注射液对伴高同型半胱氨酸血症的高血压肾病患者心、肾功能的影响。方法：采用随机数字表法将76例高血压肾病伴高同型半胱氨酸血症患者随机分成研究组和对照组，每组各38例。两组均予以常规治疗措施，研究组则在上述基础上联合肾康注射液方案，持续治疗4周。观察比较两组治疗前后肾功能指标[血肌酐(SCr)、血尿素氮(BUN)、内生肌酐清除率(Ccr)]、肾损伤标志物[血清β2-微球蛋白(β2-MG)、血清胱抑素C(Cys-C)]、心功能指标[左室射血分数(LVEF)、心室舒张期末内径(LVIDd)、左心室收缩末期内径(LVIDs)]、炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]及动脉粥样硬化危险因子[同型半胱氨酸(Hcy)、内皮素]水平及不良反应的发生情况。结果：治疗4周后，两组患者部分肾功能指标(SCr、BUN)、肾损伤标志物(血清β2-MG、血清Cys-C)、部分心功能指标(LVIDd、LVIDs)、炎性因子(CRP、TNF-α、IL-6)及动脉粥样硬化危险因子(Hcy、内皮素)水平均较治疗前明显降低，且研究组以上指标均显著低于对照组(P均＜0.05)；LVEF及Ccr水平则较治疗前明显提升，且研究组以上指标均显著高于对照组，差异均有统计学意义(P均＜0.05)。两组患者均无不良反应发生(P＞0.05)。结论：肾康注射液用于高血压肾病伴高同型半胱氨酸血症患者的临床治疗对延缓其肾损伤进程、改善患者心、肾功能及降低动脉粥样硬化形成风险等具有积极意义。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Shenkang injection on the renal and cardiac function of hypertensive nephropathy patients complicated with hyperhomocysteinemia. Methods: A total of 76 patients with hypertensive nephropathy complicated with hyperhomocysteinemia were divided into the study group and the control group with 38 cases in each group. Both groups were given routine treatment, and the study group was additionally treated with Shenkang injection for 4 weeks. The renal function index[serum creatinine (SCr), blood urea nitrogen (BUN), endogenous creatinine clearance rate (Ccr)], renal injury markers [serum β2- microglobulin (β2-MG), serum cystatin C (Cys-C)], cardiac function index[left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVIDd), left ventricular end systolic diameter (LVIDs)], inflammatory factors [C reactive protein (CRP), tumor necrosis factor α (TNF- α), interleukin -6 (IL-6)] and risk factors of atherosclerosis [homocysteine (Hcy), endothelin (ET)] and the incidence of adverse reactions were compared between the two groups. Results: At 4 weeks after treatment, the levels of renal function indexes (SCr, BUN), renal injury markers, some cardiac function indexes (LVIDd, LVIDs), inflammatory factors and risk factors of atherosclerosis were significantly lower than those before treatment, and those in the study group were lower than the control group (P<0.05). The LVEF and Ccr levels were significantly higher than those before treatment, and those in study group were higher than the control group(P<0.05). There was no adverse reactions in the two groups (P>0.05). Conclusion: Shenkang injection can delay the process of renal injury, improving cardiac and renal functions and reducing the risk of atherosclerosis in the treatment of hypertensive nephropathy patients complicated with hyperhomocysteinemia. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
